A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1444 participants.

Also called NCT03882970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,444 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03882970
  • EudraCT 2018-003422-84
Other papers using this trial's data
  • Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial The lancet. Diabetes & endocrinology, 2022-06 DOI, PubMed 35468325
  • Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial The lancet. Diabetes & endocrinology, 2022-06 DOI, PubMed 35468321 PubMed links an erratum for this paper. Erratum: PMID 35752191
  • Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI Liver international : official journal of the International Association for the Study of the Liver, 2026-09 DOI, PubMed 42576670, PMC13458421 In the PMC Open Access subset under CC BY.
  • Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Lancet (London, England), 2021-08-14 DOI, PubMed 34370970
  • Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial The lancet. Diabetes & endocrinology, 2025-06 DOI, PubMed 40318682

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Greece, Hungary, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03882970. Randomized; no masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2020-12-11 (actual). Results posted on 2022-01-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Acronym
SURPASS-3
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03882970
Content hash
125d6ce9874182c84f4bcb1214bd6a30346d4d1e54f4ae64c57132abbb1b0465